These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9187920)

  • 1. Biocompatibility: complement as mediator of tissue damage and as indicator of incompatibility.
    Mollnes TE
    Exp Clin Immunogenet; 1997; 14(1):24-9. PubMed ID: 9187920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement and biocompatibility.
    Mollnes TE
    Vox Sang; 1998; 74 Suppl 2():303-7. PubMed ID: 9704460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin-coated circuits reduce complement activation and inflammatory response to cardiopulmonary bypass.
    Tamim M; Demircin M; Guvener M; Peker O; Yilmaz M
    Panminerva Med; 1999 Sep; 41(3):193-8. PubMed ID: 10568115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of complement in biomaterial-induced inflammation.
    Nilsson B; Ekdahl KN; Mollnes TE; Lambris JD
    Mol Immunol; 2007 Jan; 44(1-3):82-94. PubMed ID: 16905192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation.
    Lappegård KT; Fung M; Bergseth G; Riesenfeld J; Lambris JD; Videm V; Mollnes TE
    Ann Thorac Surg; 2004 Mar; 77(3):932-41. PubMed ID: 14992902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Artificial surface-induced cytokine synthesis: effect of heparin coating and complement inhibition.
    Lappegård KT; Fung M; Bergseth G; Riesenfeld J; Mollnes TE
    Ann Thorac Surg; 2004 Jul; 78(1):38-44; discussion 44-5. PubMed ID: 15223398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement activation and bioincompatibility. The terminal complement complex for evaluation and surface modification with heparin for improvement of biomaterials.
    Mollnes TE; Videm V; Riesenfeld J; Garred P; Svennevig JL; Fosse E; Hogasen K; Harboe M
    Clin Exp Immunol; 1991 Oct; 86 Suppl 1(Suppl 1):21-6. PubMed ID: 1934602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in assay of complement function and activation.
    Harboe M; Thorgersen EB; Mollnes TE
    Adv Drug Deliv Rev; 2011 Sep; 63(12):976-87. PubMed ID: 21664392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A closed perfusion system with heparin coating and centrifugal pump improves cardiopulmonary bypass biocompatibility in elderly patients.
    Lindholm L; Westerberg M; Bengtsson A; Ekroth R; Jensen E; Jeppsson A
    Ann Thorac Surg; 2004 Dec; 78(6):2131-8; discussion 2138. PubMed ID: 15561050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement activation during extracorporeal therapy: biochemistry, cell biology and clinical relevance.
    Johnson RJ
    Nephrol Dial Transplant; 1994; 9 Suppl 2():36-45. PubMed ID: 8065616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Heart surgery, cardiopulmonary bypass and inflammatory response. I. Changes in hemostasis and complement].
    Parolari A; Alamanni F; Antona C; Stanghellini M; Sandano S; Spirito R; Repossini A; Sala A; Biglioli P
    G Ital Cardiol; 1996 Apr; 26(4):431-46. PubMed ID: 8707028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass.
    Shernan SK; Fitch JC; Nussmeier NA; Chen JC; Rollins SA; Mojcik CF; Malloy KJ; Todaro TG; Filloon T; Boyce SW; Gangahar DM; Goldberg M; Saidman LJ; Mangano DT;
    Ann Thorac Surg; 2004 Mar; 77(3):942-9; discussion 949-50. PubMed ID: 14992903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surface modification with functionally active heparin.
    Riesenfeld J; Olsson P; Sanchez J; Mollnes TE
    Med Device Technol; 1995 Mar; 6(2):24-31. PubMed ID: 10155375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylcholine coating of bypass systems used for young infants does not attenuate the inflammatory response.
    Draaisma AM; Hazekamp MG; Anes N; Schoof PH; Hack CE; Sturk A; Dion RA
    Ann Thorac Surg; 2006 Apr; 81(4):1455-9. PubMed ID: 16564292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimeric tyrosine sulfate acts as an endothelial cell protectant and prevents complement activation in xenotransplantation models.
    Laumonier T; Walpen AJ; Matozan KM; Korchagina EY; Bovin NV; Haeberli A; Mohacsi PJ; Rieben R
    Xenotransplantation; 2004 May; 11(3):262-8. PubMed ID: 15099206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelial cell protection and complement inhibition in xenotransplantation: a novel in vitro model using whole blood.
    Banz Y; Cung T; Korchagina EY; Bovin NV; Haeberli A; Rieben R
    Xenotransplantation; 2005 Nov; 12(6):434-43. PubMed ID: 16202066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoporesize affects complement activation.
    Ferraz N; Nilsson B; Hong J; Karlsson Ott M
    J Biomed Mater Res A; 2008 Dec; 87(3):575-81. PubMed ID: 18186072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement activation and cardiovascular disease.
    Bjerre M; Hansen TK; Flyvbjerg A
    Horm Metab Res; 2008 Sep; 40(9):626-34. PubMed ID: 18792874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quartz crystal microbalance-with dissipation monitoring (QCM-D) for real time measurements of blood coagulation density and immune complement activation on artificial surfaces.
    Andersson M; Andersson J; Sellborn A; Berglin M; Nilsson B; Elwing H
    Biosens Bioelectron; 2005 Jul; 21(1):79-86. PubMed ID: 15967354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro hemocompatibility of self-assembled monolayers displaying various functional groups.
    Sperling C; Schweiss RB; Streller U; Werner C
    Biomaterials; 2005 Nov; 26(33):6547-57. PubMed ID: 15939466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.